← Back to Search

Glucagon-like peptide-1 (GLP-1) receptor agonist

Tirzepatide for Obesity (SURMOUNT-4 Trial)

Phase 3
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up randomization (week 36), week 88
Awards & highlights

Summary

This trial tested tirzepatide, a weight-loss medication, in people who are obese or overweight. The goal was to see how well it helps maintain weight loss. Participants first took tirzepatide, then either continued it or switched to another treatment. The study lasted several years. Tirzepatide is a novel medication effective in treating obesity, showing significant weight loss.

Eligible Conditions
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~randomization (week 36), week 88
This trial's timeline: 3 weeks for screening, Varies for treatment, and randomization (week 36), week 88 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percent Change From Randomization in Body Weight at Week 88
Secondary study objectives
Change From Baseline in BMI
Change From Baseline in Body Weight
Change From Baseline in Fasting Glucose
+22 more

Side effects data

From 2022 Phase 3 trial • 210 Patients • NCT05024032
40%
Diarrhoea
30%
Nausea
27%
Decreased appetite
23%
Upper respiratory tract infection
19%
Abdominal distension
11%
Vomiting
11%
Gastroenteritis
9%
Flatulence
9%
Abortion induced
7%
Abdominal pain upper
7%
Gingivitis
7%
Amylase increased
7%
Lipase increased
6%
Abdominal pain
6%
Injection site reaction
6%
Menstruation irregular
4%
Hepatic function abnormal
4%
Hyperuricaemia
3%
Uterine polyp
3%
Vaginal infection
3%
Dizziness
1%
Hand fracture
1%
Supraventricular tachycardia
1%
Hiccups
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
10 mg Tirzepatide
15 mg Tirzepatide

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Tirzepatide MTDExperimental Treatment1 Intervention
Participants continued tirzepatide MTD (either 10 mg or 15 mg) for an additional 52 weeks.
Group II: Tirzepatide (lead-in)Experimental Treatment1 Intervention
Participants received weekly doses of tirzepatide subcutaneously (SC) for 36 weeks, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks, as tolerated, up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.
Group III: PlaceboPlacebo Group1 Intervention
Participants received weekly doses of placebo SC for 52 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tirzepatide
FDA approved

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,640 Previous Clinical Trials
3,220,861 Total Patients Enrolled
60 Trials studying Obesity
51,804 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,358 Previous Clinical Trials
417,307 Total Patients Enrolled
42 Trials studying Obesity
31,346 Patients Enrolled for Obesity
~177 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top